Pralatrexate
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Peking University People's HospitalSmall moleculePhase 4 / ApprovedActive
BBB
74/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 75/ 100
- Competitive Position
- 73/ 100
Competitive context
127 Active assets in the Peripheral T-Cell Lymphoma, Not Otherwise Specified cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Adriamycin BeBetter Med Inc | Phase 4 | BBB |
Prednisone Tarapeutics Science Inc. | Phase 4 | BBB |
(+)-Vincristine BeBetter Med Inc | Phase 4 | BBB |
Cyclophosphamide Tarapeutics Science Inc. | Phase 4 | BBB |
Rivoceranib Ruijin Hospital | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Pralatrexate is also rated in:
Nodal T-follicular helper cell lymphoma, follicular typeActive
BB
Indicative · Phase 3
64 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →